It was introduced into clinical practice initially in Japan in 1990. The rights for sevoflurane in the US and other countries are held by Abbott Laboratories.
Sevoflurane forms at least two degradation products, Compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] and Compound B [1,1,1,3,3-pentafluoro-2-(fluoromethoxy)-3-methoxypropane], on contact with the soda lime in a rebreathing apparatus, which absorbs exhaled carbon dioxide, especially at higher temperatures and when the soda lime is desiccated. Compound A has been shown to cause renal necrosis in rats. In humans, direct histological evidence of renal toxicity has not been demonstrated, although there is dose-related proteinuria, glycosuria and enzymuria. During low-flow anaesthesia, when the lower fresh gas flow leads to decreased flushing of the circuit and increased temperature of the soda lime, Compound A may build up to clinically significant levels. As a result, sevoflurane is sometimes administered with a minimum fresh gas flow of 2 liters per minute, making it a relatively expensive choice for maintaining general anesthesia.
|Boiling point:||58.6 °C||(at 101.325 kPa)|
|Density:||1.517–1.522 g/cm³||(at 20 °C)|
|MAC :||2 vol %|
|Molecular Weight:||200 u|
|Vapor pressure:||157 mmHg (20.9 kPa)||(at 20 °C)|
|197 mmHg (26.3 kPa)||(at 25 °C)|
|317 mmHg (42.3 kPa)||(at 36 °C)|
|Blood:Gas Partition Coefficient:||0.68|
|Oil:Gas Partition Coefficient:||47|